Importance: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Despite the recent approval of several new agents, long-term disease control remains elusive for most patients. Administration of 27.12 MHz radiofrequency (RF) electromagnetic fields (EMF) by means of a spoon-shaped antenna (TheraBionic P1 device) placed on the anterior part of the tongue… Continue reading Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced #hepatocellular carcinoma
Category: Hepatology
#EGFR activation limits the response of #liver cancer to lenvatinib
Hepatocellular carcinoma (HCC)—the most common form of liver cancer—is an aggressive malignancy with few effective treatment options1. Lenvatinib is a small-molecule inhibitor of multiple receptor tyrosine kinases that is used for the treatment of patients with advanced HCC, but this drug has only limited clinical benefit2. Here, using a kinome-centred CRISPR–Cas9 genetic screen, we show… Continue reading #EGFR activation limits the response of #liver cancer to lenvatinib
Effects of #Tamoxifen vs. Toremifene on #fatty liver development and lipid profiles in #breast Cancer
Tamoxifen (TAM) and Toremifene (TOR), two kinds of selective estrogen receptor modulators (SERMs), have equal efficacy in breast cancer patients. However, TAM has been proved to affect serum lipid profiles and cause fatty liver disease. The study aimed to compare the effects of TAM and TOR on fatty liver development and lipid profiles. MethodsThis study… Continue reading Effects of #Tamoxifen vs. Toremifene on #fatty liver development and lipid profiles in #breast Cancer
Immunotherapy-based targeting of MSLN+ activated portal #fibroblasts is a strategy for treatment of cholestatic liver #fibrosis
Mesothelin (Msln) expression is increased in tissue fibroblasts of damaged liver and other organs and Msln is a common mediator of liver, lung, and kidney fibrosis. We show that anti-Msln immunotoxins kill the Msln-expressing fibroblasts and reduce collagen type I deposition in fibrotic liver, indicating that agents that specifically kill Msln-expressing cells should be a… Continue reading Immunotherapy-based targeting of MSLN+ activated portal #fibroblasts is a strategy for treatment of cholestatic liver #fibrosis
Auto-immune #hepatitis following #COVID vaccination
Unprecedented loss of life due to the COVID pandemic has necessitated the development of several vaccines in record time. Most of these vaccines have received approval without being extensively whetted for their adverse effect and efficacy profiles. Most adverse effects have been mild, nonetheless, more serious thromboembolic events have also been reported. Autoimmune hepatitis (AIH)… Continue reading Auto-immune #hepatitis following #COVID vaccination
Incidence of #liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) increases morbidity and mortality. However, patients in biopsy-based cohorts are highly selected and the absolute risks of liver- and non-liver outcomes in NAFLD in population remains undefined. We analyzed both liver-related and non-liver-related outcomes in Finnish population cohorts of NAFLD. MethodsWe included 10993 individuals (6707 men, mean age 53.3±12.6 years)… Continue reading Incidence of #liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease
Intact Fasting #Insulin Identifies Nonalcoholic Fatty #Liver Disease in Patients Without Diabetes
Patients with nonalcoholic fatty liver disease (NAFLD) are characterized by insulin resistance and hyperinsulinism. However, insulin resistance measurements have not been shown to be good diagnostic tools to predict NAFLD in prior studies. ObjectiveWe aimed to assess a newly validated method to measure intact molecules of insulin by mass spectrometry to predict NAFLD. MethodsPatients underwent… Continue reading Intact Fasting #Insulin Identifies Nonalcoholic Fatty #Liver Disease in Patients Without Diabetes
A critical role of hepatic #GABA in the metabolic dysfunction and #hyperphagia of #obesity
Hepatic lipid accumulation is a hallmark of type II diabetes (T2D) associated with hyperinsulinemia, insulin resistance, and hyperphagia. Hepatic synthesis of GABA, catalyzed by GABA-transaminase (GABA-T), is upregulated in obese mice. To assess the role of hepatic GABA production in obesity-induced metabolic and energy dysregulation, we treated mice with two pharmacologic GABA-T inhibitors and knocked… Continue reading A critical role of hepatic #GABA in the metabolic dysfunction and #hyperphagia of #obesity
#Fibrosis improvement in patients with #HCV treated with direct-acting antivirals
More prospective studies are needed to characterize fibrosis improvement in patients with hepatitis C virus (HCV) who are treated with direct-acting antivirals (DAAs). The aims of this study were to assess changes in elastography scores from baseline to 1-year follow-up in patients with HCV, to identify factors that were independently associated with improvement in fibrosis… Continue reading #Fibrosis improvement in patients with #HCV treated with direct-acting antivirals
